1
|
Bedini A, Boutin JA, Legros C, Zlotos DP, Spadoni G. Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey. J Pineal Res 2024; 76:e12953. [PMID: 38682544 DOI: 10.1111/jpi.12953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 03/05/2024] [Accepted: 03/24/2024] [Indexed: 05/01/2024]
Abstract
The search for melatonin receptor agonists formed the main part of melatonin medicinal chemistry programs for the last three decades. In this short review, we summarize the two main aspects of these programs: the development of all the necessary tools to characterize the newly synthesized ligands at the two melatonin receptors MT1 and MT2, and the medicinal chemist's approaches to find chemically diverse ligands at these receptors. Both strategies are described. It turns out that the main source of tools were industrial laboratories, while the medicinal chemistry was mainly carried out in academia. Such complete accounts are interesting, as they delineate the spirits in which the teams were working demonstrating their strength and innovative character. Most of the programs were focused on nonselective agonists and few of them reached the market. In contrast, discovery of MT1-selective agonists and melatonergic antagonists with proven in vivo activity and MT1 or MT2-selectivity is still in its infancy, despite the considerable interest that subtype selective compounds may bring in the domain, as the physiological respective roles of the two subtypes of melatonin receptors, is still poorly understood. Poly-pharmacology applications and multitarget ligands have also been considered.
Collapse
MESH Headings
- Ligands
- Humans
- Animals
- Receptor, Melatonin, MT2/metabolism
- Receptor, Melatonin, MT2/agonists
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT1/agonists
- Receptor, Melatonin, MT1/antagonists & inhibitors
- Receptors, Melatonin/metabolism
- Receptors, Melatonin/agonists
- Melatonin/metabolism
- History, 20th Century
Collapse
Affiliation(s)
- Annalida Bedini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Urbino, Italy
| | - Jean A Boutin
- Laboratory of Neuroendocrine Endocrine and Germinal Differentiation and Communication (NorDiC), Univ Rouen Normandie, Inserm, NorDiC, Rouen, France
| | | | - Darius P Zlotos
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, Egypt
| | - Gilberto Spadoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Urbino, Italy
| |
Collapse
|
2
|
Elisi GM, Scalvini L, Lodola A, Bedini A, Spadoni G, Rivara S. In silico drug discovery of melatonin receptor ligands with therapeutic potential. Expert Opin Drug Discov 2022; 17:343-354. [PMID: 35255751 DOI: 10.1080/17460441.2022.2043846] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION The neurohormone melatonin (N-acetyl-5-methoxytryptamine) regulates circadian rhythms exerting a variety of effects in the central nervous system and in periphery. These activities are mainly mediated by activation of MT1 and MT2 GPCRs. MT1/MT2 agonist compounds are used clinically for insomnia, depression, and circadian rhythm disturbances. AREA COVERED The following review describes the design strategies that have led to the identification of melatonin receptor ligands, guided by in silico approaches and molecular modeling. Initial ligand-based design, mainly relying on pharmacophore modeling and 3D-QSAR, has been flanked by structure-based virtual screening, given the recent availability of MT1 and MT2 crystal structures. Receptor ligands with different activity profiles, agonist/antagonist and subtype-selective compounds, are available. EXPERT OPINION An insight on the pharmacological characterization and therapeutic perspectives for relevant ligands is provided. In silico drug discovery has been instrumental in the design of novel ligands targeting melatonin receptors. Ligand-based approaches has led to the construction of a solid framework defining structure-activity relationships to obtain compounds with a tailored pharmacological profile. Structure-based techniques could integrate previous knowledge and provide compounds with novel chemotypes and pharmacological activity as drug candidates for disease conditions in which melatonin receptor ligands are currently being investigated, including cancer and pain.
Collapse
Affiliation(s)
- Gian Marco Elisi
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| | - Laura Scalvini
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| | - Alessio Lodola
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| | - Annalida Bedini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy
| | - Gilberto Spadoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy
| | - Silvia Rivara
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| |
Collapse
|
3
|
Cecon E, Liu L, Jockers R. Melatonin receptor structures shed new light on melatonin research. J Pineal Res 2019; 67:e12606. [PMID: 31442321 DOI: 10.1111/jpi.12606] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Revised: 08/17/2019] [Accepted: 08/18/2019] [Indexed: 01/02/2023]
Abstract
The tryptophan derivative melatonin is an evolutionary old molecule that is involved in a pleiotropy of physiological functions. In humans, age-related decline of circulating melatonin levels and/or dysregulation of its circadian synthesis pattern have been associated with several disorders and disease states. Several molecular targets have been proposed for melatonin since its discovery, in 1959. Among them, melatonin MT1 and MT2 receptors are the best characterized melatonin targets, mediating melatonin effects in a variety of tissues. They belong to the superfamily of G protein-coupled receptors. Two back-to-back articles published in the "Nature" Journal earlier this year present the first crystal structures of the human MT1 and MT2 in its inactive states. Here, we will briefly outline the discovery path of melatonin receptors until their structural elucidation and discuss how these new findings will guide future research toward a better understanding of their function and rational drug design.
Collapse
MESH Headings
- Animals
- History, 20th Century
- History, 21st Century
- Humans
- Melatonin/chemistry
- Melatonin/history
- Melatonin/metabolism
- Protein Structure, Tertiary
- Receptor, Melatonin, MT1/chemistry
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT2/chemistry
- Receptor, Melatonin, MT2/metabolism
- Signal Transduction
Collapse
Affiliation(s)
- Erika Cecon
- Institut Cochin, CNRS, INSERM, Université de Paris, Paris, France
| | - Lei Liu
- Institut Cochin, CNRS, INSERM, Université de Paris, Paris, France
- Cellular Signaling Laboratory, International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of Ministry of Education, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
| | - Ralf Jockers
- Institut Cochin, CNRS, INSERM, Université de Paris, Paris, France
| |
Collapse
|
4
|
Sulkava S, Muggalla P, Sulkava R, Ollila HM, Peuralinna T, Myllykangas L, Kaivola K, Stone DJ, Traynor BJ, Renton AE, Rivera AM, Helisalmi S, Soininen H, Polvikoski T, Hiltunen M, Tienari PJ, Huttunen HJ, Paunio T. Melatonin receptor type 1A gene linked to Alzheimer's disease in old age. Sleep 2019; 41:5049081. [PMID: 29982836 PMCID: PMC6047434 DOI: 10.1093/sleep/zsy103] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 05/18/2018] [Indexed: 11/14/2022] Open
Abstract
Disruption of the circadian rhythms is a frequent preclinical and clinical manifestation of Alzheimer’s disease. Furthermore, it has been suggested that shift work is a risk factor for Alzheimer’s disease. Previously, we have reported association of intolerance to shift work (job-related exhaustion in shift workers) with a variant rs12506228A, which is situated close to melatonin receptor type 1A gene (MTNR1A) and linked to MTNR1A brain expression levels. Here, we studied association of that variant with clinical and neuropathological Alzheimer’s disease in a Finnish whole-population cohort Vantaa 85+ (n = 512, participants over 85 years) and two follow-up cohorts. Rs12506228A was associated with clinical Alzheimer’s disease (p = 0.000073). Analysis of post-mortem brain tissues showed association with higher amount of neurofibrillary tangles (p = 0.0039) and amyloid beta plaques (p = 0.0041). We then followed up the associations in two independent replication samples. Replication for the association with clinical Alzheimer’s disease was detected in Kuopio 75+ (p = 0.012, n = 574), but not in the younger case-control sample (n = 651 + 669). While melatonin has been established in regulation of circadian rhythms, an independent role has been also shown for neuroprotection and specifically for anti-amyloidogenic effects. Indeed, in vitro, RNAi mediated silencing of MTNR1A increased the amyloidogenic processing of amyloid precursor protein (APP) in neurons, whereas overexpression decreased it. Our findings suggest variation close to MTNR1A as a shared genetic risk factor for intolerance to shift work and Alzheimer’s disease in old age. The genetic associations are likely to be mediated by differences in MTNR1A expression, which, in turn, modulate APP metabolism.
Collapse
Affiliation(s)
- Sonja Sulkava
- Department of Health, Genomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland.,Department of Psychiatry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | | | - Raimo Sulkava
- Unit of Geriatrics, University of Eastern Finland, Kuopio, Finland
| | - Hanna M Ollila
- Department of Health, Genomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland.,Department of Psychiatry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.,Stanford University Center for Sleep Sciences, Palo Alto, CA
| | - Terhi Peuralinna
- Research Program of Molecular Neurology, University of Helsinki, Helsinki, Finland
| | - Liisa Myllykangas
- Department of Pathology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Karri Kaivola
- Research Program of Molecular Neurology, University of Helsinki, Helsinki, Finland
| | - David J Stone
- Genetics and Pharmacogenomics, Merck Research Labs, West Point, PA
| | - Bryan J Traynor
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
| | - Alan E Renton
- Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Alberto M Rivera
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
| | - Seppo Helisalmi
- Institute of Clinical Medicine - Neurology, University of Eastern Finland and NeuroCenter, Kuopio University Hospital, Kuopio, Finland
| | - Hilkka Soininen
- Institute of Clinical Medicine - Neurology, University of Eastern Finland and NeuroCenter, Kuopio University Hospital, Kuopio, Finland
| | - Tuomo Polvikoski
- Institute for Ageing and Health, Newcastle University, Newcastle, UK
| | - Mikko Hiltunen
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.,NeuroCenter, Kuopio University Hospital, Kuopio, Finland
| | - Pentti J Tienari
- Research Program of Molecular Neurology, University of Helsinki, Helsinki, Finland
| | | | - Tiina Paunio
- Department of Health, Genomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland.,Department of Psychiatry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| |
Collapse
|
5
|
Karamitri A, Sadek MS, Journé AS, Gbahou F, Gerbier R, Osman MB, Habib SAM, Jockers R, Zlotos DP. O-linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors. Bioorg Chem 2019; 85:349-356. [PMID: 30658234 DOI: 10.1016/j.bioorg.2019.01.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Revised: 12/30/2018] [Accepted: 01/02/2019] [Indexed: 12/17/2022]
Abstract
A series of dimeric melatonin analogues 3a-e obtained by connecting two melatonin molecules through the methoxy oxygen atoms with spacers spanning 16-24 atoms and the agomelatine dimer 7 were synthesized and characterized in 2-[125-I]-iodomelatonin binding assays, bioluminescence resonance energy transfer (BRET) experiments, and in functional cAMP and β-arrestin recruitment assays at MT1 and MT2 receptors. The binding affinity of 3a-e generally increased with increasing linker length. Bivalent ligands 3a-e increased BRET signals of MT1 dimers up to 3-fold compared to the monomeric control ligand indicating the simultaneous binding of the two pharmacophores to dimeric receptors. Bivalent ligands 3c and 7 exhibited important changes in functional properties on the Gi/cAMP pathway but not on the β-arrestin pathway compared to their monomeric counterparts. Interestingly, 3c (20 atoms spacer) shows inverse agonistic properties at MT2 on the Gi/cAMP pathway. In conclusion, these findings indicate that O-linked melatonin dimers are promising tools to develop signaling pathway-based bivalent melatonin receptor ligands.
Collapse
Affiliation(s)
- Angeliki Karamitri
- Inserm, U1016, Institut Cochin, Paris, France; CNRS UMR 8104, Paris, France; Univ. Paris Descartes, Sorbonne Paris Cite, Paris, France
| | - Mirna S Sadek
- The German University in Cairo, Department of Pharmaceutical Chemistry, New Cairo City, 11835 Cairo, Egypt.
| | - Anne-Sophie Journé
- Inserm, U1016, Institut Cochin, Paris, France; CNRS UMR 8104, Paris, France; Univ. Paris Descartes, Sorbonne Paris Cite, Paris, France
| | - Florence Gbahou
- Inserm, U1016, Institut Cochin, Paris, France; CNRS UMR 8104, Paris, France; Univ. Paris Descartes, Sorbonne Paris Cite, Paris, France.
| | - Romain Gerbier
- Inserm, U1016, Institut Cochin, Paris, France; CNRS UMR 8104, Paris, France; Univ. Paris Descartes, Sorbonne Paris Cite, Paris, France
| | - Mai B Osman
- The German University in Cairo, Department of Pharmaceutical Chemistry, New Cairo City, 11835 Cairo, Egypt
| | - Samy A M Habib
- The German University in Cairo, Department of Pharmaceutical Chemistry, New Cairo City, 11835 Cairo, Egypt
| | - Ralf Jockers
- Inserm, U1016, Institut Cochin, Paris, France; CNRS UMR 8104, Paris, France; Univ. Paris Descartes, Sorbonne Paris Cite, Paris, France.
| | - Darius P Zlotos
- The German University in Cairo, Department of Pharmaceutical Chemistry, New Cairo City, 11835 Cairo, Egypt.
| |
Collapse
|
6
|
Benleulmi-Chaachoua A, Hegron A, Le Boulch M, Karamitri A, Wierzbicka M, Wong V, Stagljar I, Delagrange P, Ahmad R, Jockers R. Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure. Cell Mol Life Sci 2018; 75:4357-4370. [PMID: 30043140 PMCID: PMC11105639 DOI: 10.1007/s00018-018-2876-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2018] [Revised: 06/26/2018] [Accepted: 07/16/2018] [Indexed: 12/11/2022]
Abstract
Melatonin, a neuro-hormone released by the pineal gland, has multiple effects in the central nervous system including the regulation of dopamine (DA) levels, but how melatonin accomplishes this task is not clear. Here, we show that melatonin MT1 and MT2 receptors co-immunoprecipitate with the DA transporter (DAT) in mouse striatal synaptosomes. Increased DA re-uptake and decreased amphetamine-induced locomotor activity were observed in the striatum of mice with targeted deletion of MT1 or MT2 receptors. In vitro experiments confirmed the interactions and recapitulated the inhibitory effect of melatonin receptors on DA re-uptake. Melatonin receptors retained DAT in the endoplasmic reticulum in its immature non-glycosylated form. In conclusion, we reveal one of the first molecular complexes between G protein-coupled receptors (MT1 and MT2) and transporters (DAT) in which melatonin receptors regulate the availability of DAT at the plasma membrane, thus limiting the striatal DA re-uptake capacity in mice.
Collapse
MESH Headings
- Animals
- Cell Membrane/metabolism
- Corpus Striatum/metabolism
- Dopamine/metabolism
- Dopamine Plasma Membrane Transport Proteins/genetics
- Dopamine Plasma Membrane Transport Proteins/metabolism
- HEK293 Cells
- Humans
- Male
- Mice, Inbred C57BL
- Mice, Knockout
- Motor Activity/genetics
- Protein Binding
- Receptor, Melatonin, MT1/genetics
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT2/genetics
- Receptor, Melatonin, MT2/metabolism
- Synaptosomes/metabolism
Collapse
Affiliation(s)
- Abla Benleulmi-Chaachoua
- Inserm, U1016, Institut Cochin, 22 Rue Mechain, 75014, Paris, France
- CNRS, UMR 8104, 22 Rue Mechain, 75014, Paris, France
- University of Paris Descartes, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France
| | - Alan Hegron
- Inserm, U1016, Institut Cochin, 22 Rue Mechain, 75014, Paris, France
- CNRS, UMR 8104, 22 Rue Mechain, 75014, Paris, France
- University of Paris Descartes, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France
| | - Marine Le Boulch
- Inserm, U1016, Institut Cochin, 22 Rue Mechain, 75014, Paris, France
- CNRS, UMR 8104, 22 Rue Mechain, 75014, Paris, France
- University of Paris Descartes, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France
| | - Angeliki Karamitri
- Inserm, U1016, Institut Cochin, 22 Rue Mechain, 75014, Paris, France
- CNRS, UMR 8104, 22 Rue Mechain, 75014, Paris, France
- University of Paris Descartes, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France
| | - Marta Wierzbicka
- Donnelly Centre, Department of Biochemistry, Faculty of Medicine, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
- Department of Molecular Genetics, Faculty of Medicine, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
| | - Victoria Wong
- Donnelly Centre, Department of Biochemistry, Faculty of Medicine, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
- Department of Molecular Genetics, Faculty of Medicine, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
| | - Igor Stagljar
- Donnelly Centre, Department of Biochemistry, Faculty of Medicine, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
- Department of Molecular Genetics, Faculty of Medicine, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
| | - Philippe Delagrange
- Pôle d'Innovation Thérapeutique Neuropsychiatrie, Institut de Recherches Servier, 125 Chemin de Ronde, 78290, Croissy, France
| | - Raise Ahmad
- Inserm, U1016, Institut Cochin, 22 Rue Mechain, 75014, Paris, France
- CNRS, UMR 8104, 22 Rue Mechain, 75014, Paris, France
- University of Paris Descartes, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France
| | - Ralf Jockers
- Inserm, U1016, Institut Cochin, 22 Rue Mechain, 75014, Paris, France.
- CNRS, UMR 8104, 22 Rue Mechain, 75014, Paris, France.
- University of Paris Descartes, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France.
| |
Collapse
|
7
|
Karamitri A, Plouffe B, Bonnefond A, Chen M, Gallion J, Guillaume JL, Hegron A, Boissel M, Canouil M, Langenberg C, Wareham NJ, Le Gouill C, Lukasheva V, Lichtarge O, Froguel P, Bouvier M, Jockers R. Type 2 diabetes-associated variants of the MT 2 melatonin receptor affect distinct modes of signaling. Sci Signal 2018; 11:11/545/eaan6622. [PMID: 30154102 DOI: 10.1126/scisignal.aan6622] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Melatonin is produced during the night and regulates sleep and circadian rhythms. Loss-of-function variants in MTNR1B, which encodes the melatonin receptor MT2, a G protein-coupled receptor (GPCR), are associated with an increased risk of type 2 diabetes (T2D). To identify specific T2D-associated signaling pathway(s), we profiled the signaling output of 40 MT2 variants by monitoring spontaneous (ligand-independent) and melatonin-induced activation of multiple signaling effectors. Genetic association analysis showed that defects in the melatonin-induced activation of Gαi1 and Gαz proteins and in spontaneous β-arrestin2 recruitment to MT2 were the most statistically significantly associated with an increased T2D risk. Computational variant impact prediction by in silico evolutionary lineage analysis strongly correlated with the measured phenotypic effect of each variant, providing a predictive tool for future studies on GPCR variants. Together, this large-scale functional study provides an operational framework for the postgenomic analysis of the multiple GPCR variants present in the human population. The association of T2D risk with signaling pathway-specific defects opens avenues for pathway-specific personalized therapeutic intervention and reveals the potential relevance of MT2 function during the day, when melatonin is undetectable, but spontaneous activity of the receptor occurs.
Collapse
Affiliation(s)
- Angeliki Karamitri
- Inserm, U1016, Institut Cochin, Paris, France.,CNRS UMR 8104, Paris, France.,Université Paris Descartes, Paris, France
| | - Bianca Plouffe
- Institute for Research in Immunology and Cancer and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Québec H3C 3J7, Canada
| | - Amélie Bonnefond
- Université Lille, CNRS UMR 8199-EGID, Institut Pasteur de Lille, Lille, France
| | - Min Chen
- Inserm, U1016, Institut Cochin, Paris, France.,CNRS UMR 8104, Paris, France.,Université Paris Descartes, Paris, France
| | - Jonathan Gallion
- Structural Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jean-Luc Guillaume
- Inserm, U1016, Institut Cochin, Paris, France.,CNRS UMR 8104, Paris, France.,Université Paris Descartes, Paris, France
| | - Alan Hegron
- Inserm, U1016, Institut Cochin, Paris, France.,CNRS UMR 8104, Paris, France.,Université Paris Descartes, Paris, France
| | - Mathilde Boissel
- Université Lille, CNRS UMR 8199-EGID, Institut Pasteur de Lille, Lille, France
| | - Mickaël Canouil
- Université Lille, CNRS UMR 8199-EGID, Institut Pasteur de Lille, Lille, France
| | - Claudia Langenberg
- Medical Research Council (MRC) Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK
| | - Nicholas J Wareham
- Medical Research Council (MRC) Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK
| | - Christian Le Gouill
- Institute for Research in Immunology and Cancer and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Québec H3C 3J7, Canada
| | - Viktoria Lukasheva
- Institute for Research in Immunology and Cancer and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Québec H3C 3J7, Canada
| | - Olivier Lichtarge
- Structural Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Philippe Froguel
- Université Lille, CNRS UMR 8199-EGID, Institut Pasteur de Lille, Lille, France. .,Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, W12 0NN London, UK
| | - Michel Bouvier
- Institute for Research in Immunology and Cancer and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, Québec H3C 3J7, Canada.
| | - Ralf Jockers
- Inserm, U1016, Institut Cochin, Paris, France. .,CNRS UMR 8104, Paris, France.,Université Paris Descartes, Paris, France
| |
Collapse
|
8
|
Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br J Pharmacol 2018; 175:3263-3280. [PMID: 28707298 PMCID: PMC6057902 DOI: 10.1111/bph.13950] [Citation(s) in RCA: 157] [Impact Index Per Article: 26.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Revised: 07/05/2017] [Accepted: 07/10/2017] [Indexed: 12/15/2022] Open
Abstract
Melatonin, N-acetyl-5-methoxytryptamine, an evolutionally old molecule, is produced by the pineal gland in vertebrates, and it binds with high affinity to melatonin receptors, which are members of the GPCR family. Among the multiple effects attributed to melatonin, we will focus here on those that are dependent on the activation of the two mammalian MT1 and MT2 melatonin receptors. We briefly summarize the latest developments on synthetic melatonin receptor ligands, including multi-target-directed ligands, and the characterization of signalling-biased ligands. We discuss signalling pathways activated by melatonin receptors that appear to be highly cell- and tissue-dependent, emphasizing the impact of system bias on the functional outcome. Different proteins have been demonstrated to interact with melatonin receptors, and thus, we postulate that part of this system bias has its molecular basis in differences of the expression of receptor-associated proteins including heterodimerization partners. Finally, bias at the level of the receptor, by the expression of genetic receptor variants, will be discussed to show how a modified receptor function can have an effect on the risk for common diseases like type 2 diabetes in humans. LINKED ARTICLES: This article is part of a themed section on Recent Developments in Research of Melatonin and its Potential Therapeutic Applications. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc.
Collapse
Affiliation(s)
- Erika Cecon
- Institut CochinInserm, U1016ParisFrance
- CNRS UMR 8104ParisFrance
- Univ. Paris Descartes, Sorbonne Paris CitéParisFrance
| | - Atsuro Oishi
- Institut CochinInserm, U1016ParisFrance
- CNRS UMR 8104ParisFrance
- Univ. Paris Descartes, Sorbonne Paris CitéParisFrance
| | - Ralf Jockers
- Institut CochinInserm, U1016ParisFrance
- CNRS UMR 8104ParisFrance
- Univ. Paris Descartes, Sorbonne Paris CitéParisFrance
| |
Collapse
|
9
|
Boutin JA, Bonnaud A, Brasseur C, Bruno O, Lepretre N, Oosting P, Coumailleau S, Delagrange P, Nosjean O, Legros C. New MT₂ Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists. Int J Mol Sci 2017; 18:E1347. [PMID: 28644418 PMCID: PMC5535840 DOI: 10.3390/ijms18071347] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Revised: 06/02/2017] [Accepted: 06/20/2017] [Indexed: 12/28/2022] Open
Abstract
The search for melatonin receptor agonists and antagonists specific towards one of the receptor subtypes will extend our understanding of the role of this system in relaying circadian information to the body. A series of compounds derived from a hit compound discovered in a screening process led to powerful agonists specific for one of the isoform of the melatonin receptor namely, MT₂. The compounds are based on a poorly explored skeleton in the molecular pharmacology of melatonin. By changing the steric hindrance of one substituent (i.e., from a hydrogen atom to a tributylstannyl group), we identified a possible partial agonist that could lead to antagonist analogues. The functionalities of these compounds were measured with a series of assays, including the binding of GTPγS, the inhibition of the cyclic AMP production, the β-arrestin recruitment, and the cell shape changes as determined by cellular dielectric spectroscopy (CellKey®). The variations between the compounds are discussed.
Collapse
Affiliation(s)
- Jean A Boutin
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
- Pôle d'Expertise Recherches & BioPharmacie, Institut de Recherches Internationales SERVIER, 92150 Suresnes, France.
| | - Anne Bonnaud
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
| | - Chantal Brasseur
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
| | - Olivier Bruno
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
| | | | | | - Sophie Coumailleau
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
| | - Philippe Delagrange
- Pôle d'Innovations Thérapeutiques en Neurosciences, Institut de Recherches, SERVIER, 78290 Croissy-sur-Seine, France.
| | - Olivier Nosjean
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
- Pôle d'Expertise Recherches & BioPharmacie, Institut de Recherches Internationales SERVIER, 92150 Suresnes, France.
| | - Céline Legros
- Pôle d'Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France.
| |
Collapse
|
10
|
Legros C, Brasseur C, Delagrange P, Ducrot P, Nosjean O, Boutin JA. Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. J Pharmacol Exp Ther 2016; 356:681-92. [PMID: 26759496 DOI: 10.1124/jpet.115.229989] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 01/11/2016] [Indexed: 12/15/2022] Open
Abstract
Melatonin exerts a variety of physiologic activities that are mainly relayed through the melatonin receptors MT1 and MT2 Low expressions of these receptors in tissues have led to widespread experimental use of the agonist 2-[(125)I]-iodomelatonin as a substitute for melatonin. We describe three iodinated ligands: 2-(2-[(2-iodo-4,5-dimethoxyphenyl)methyl]-4,5-dimethoxy phenyl) (DIV880) and (2-iodo-N-2-[5-methoxy-2-(naphthalen-1-yl)-1H-pyrrolo[3,2-b]pyridine-3-yl])acetamide (S70254), which are specific ligands at MT2 receptors, and N-[2-(5-methoxy-1H-indol-3-yl)ethyl]iodoacetamide (SD6), an analog of 2-[(125)I]-iodomelatonin with slightly different characteristics. Here, we further characterized these new ligands with regards to their molecular pharmacology. We performed binding experiments, saturation assays, association/dissociation rate measurements, and autoradiography using sheep and rat tissues and recombinant cell lines. Our results showed that [(125)I]-S70254 is receptor, and can be used with both cells and tissue. This radioligand can be used in autoradiography. Similarly, DIV880, a partial agonist [43% of melatonin on guanosine 5'-3-O-(thio)triphosphate binding assay], selective for MT2, can be used as a tool to selectively describe the pharmacology of this receptor in tissue samples. The molecular pharmacology of both human melatonin receptors MT1 and MT2, using a series of 24 ligands at these receptors and the new radioligands, did not lead to noticeable variations in the profiles. For the first time, we described radiolabeled tools that are specific for one of the melatonin receptors (MT2). These tools are amenable to binding experiments and to autoradiography using sheep or rat tissues. These specific tools will permit better understanding of the role and implication in physiopathologic processes of the melatonin receptors.
Collapse
Affiliation(s)
- Céline Legros
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Chantal Brasseur
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Philippe Delagrange
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Pierre Ducrot
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Olivier Nosjean
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Jean A Boutin
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| |
Collapse
|
11
|
Benleulmi-Chaachoua A, Chen L, Sokolina K, Wong V, Jurisica I, Emerit MB, Darmon M, Espin A, Stagljar I, Tafelmeyer P, Zamponi GW, Delagrange P, Maurice P, Jockers R. Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons. J Pineal Res 2016; 60:95-108. [PMID: 26514267 DOI: 10.1111/jpi.12294] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Accepted: 10/26/2015] [Indexed: 01/11/2023]
Abstract
In mammals, the hormone melatonin is mainly produced by the pineal gland with nocturnal peak levels. Its peripheral and central actions rely either on its intrinsic antioxidant properties or on binding to melatonin MT1 and MT2 receptors, belonging to the G protein-coupled receptor (GPCR) super-family. Melatonin has been reported to be involved in many functions of the central nervous system such as circadian rhythm regulation, neurotransmission, synaptic plasticity, memory, sleep, and also in Alzheimer's disease and depression. However, little is known about the subcellular localization of melatonin receptors and the molecular aspects involved in neuronal functions of melatonin. Identification of protein complexes associated with GPCRs has been shown to be a valid approach to improve our understanding of their function. By combining proteomic and genomic approaches we built an interactome of MT1 and MT2 receptors, which comprises 378 individual proteins. Among the proteins interacting with MT1 , but not with MT2 , we identified several presynaptic proteins, suggesting a potential role of MT1 in neurotransmission. Presynaptic localization of MT1 receptors in the hypothalamus, striatum, and cortex was confirmed by subcellular fractionation experiments and immunofluorescence microscopy. MT1 physically interacts with the voltage-gated calcium channel Cav 2.2 and inhibits Cav 2.2-promoted Ca(2+) entry in an agonist-independent manner. In conclusion, we show that MT1 is part of the presynaptic protein network and negatively regulates Cav 2.2 activity, providing a first hint for potential synaptic functions of MT1.
Collapse
Affiliation(s)
- Abla Benleulmi-Chaachoua
- Inserm, U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Université Paris Descartes, Paris, France
| | - Lina Chen
- Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
| | - Kate Sokolina
- Donnelly Centre, Department of Biochemistry, Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Victoria Wong
- Donnelly Centre, Department of Biochemistry, Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Igor Jurisica
- Princess Margaret Cancer Centre, University Health Network and TECHNA Institute for the Advancement of Technology for Health, Toronto, ON, Canada
| | - Michel Boris Emerit
- Sorbonne Paris Cité, Université Paris Descartes, Paris, France
- Centre de Psychiatrie et Neurosciences, INSERM U894, Paris, France
| | - Michèle Darmon
- Sorbonne Paris Cité, Université Paris Descartes, Paris, France
- Centre de Psychiatrie et Neurosciences, INSERM U894, Paris, France
| | - Almudena Espin
- Inserm, U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Université Paris Descartes, Paris, France
| | - Igor Stagljar
- Donnelly Centre, Department of Biochemistry, Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | | | - Gerald W Zamponi
- Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
| | | | - Pascal Maurice
- Inserm, U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Université Paris Descartes, Paris, France
| | - Ralf Jockers
- Inserm, U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Université Paris Descartes, Paris, France
| |
Collapse
|
12
|
Sampaio LDFS, Mesquita FP, de Sousa PRM, Silva JL, Alves CN. The melatonin analog 5-MCA-NAT increases endogenous dopamine levels by binding NRH:quinone reductase enzyme in the developing chick retina. Int J Dev Neurosci 2014; 38:119-26. [PMID: 25218627 DOI: 10.1016/j.ijdevneu.2014.09.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 08/22/2014] [Accepted: 09/02/2014] [Indexed: 12/15/2022] Open
Abstract
NRH:quinone reductase (QR2) is present in the retinas of embryonic and post-hatched (PH) chicks. 5-Methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) is a QR2 ligand that increases cAMP levels in developing retinas, but it does not affect cAMP levels in CHO-QR2 cells. The dopamine quinone reductase activity of QR2 retrieves dopamine, which increases cAMP levels in developing retinas. The objective of the present study was to investigate whether 5-MCA-NAT increases endogenous dopamine levels in retinas from chick embryos and post-hatched chicks. Endogenous dopamine was measured by enzyme-linked immunosorbent assay (ELISA). 5-MCA-NAT increased retinal endogenous dopamine levels at all developmental stages studied and in PH chicks (-logEC50=11.62±0.34 M). This effect was inhibited by non-selective antagonists of receptors and melatonin binding sites N-acetyl-2-benzyltryptamine (luzindole, 5 μM), but it was not inhibited by the Mel1b melatonin receptor antagonist 4-phenyl-2-propionamidotetralin (4-P-PDOT, 10 nM). The QR2 cosubstrate, N-methyl-dihydronicotinamide (NMH) (-logEC50=6.74±0.26 M), increased endogenous dopamine levels in controls and in retinas stimulated with 5-MCA-NAT (3 nM). The QR2 inhibitor benzo[e]pyrene inhibited endogenous dopamine levels in both control (-logIC50=7.4±0.28 M) and NMH-stimulated (at 100 nM and 1 μM benzo[e]pyrene concentrations) retinas. Theoretical studies using Molegro Virtual Docking software corroborated these experimental results. We conclude that 5-MCA-NAT increases the level of endogenous dopamine via QR2. We suggest that this enzyme triggers double reduction of the dopamine quinone, recovering dopamine in retinal development.
Collapse
Affiliation(s)
- Lucia de Fatima Sobral Sampaio
- Lab. de Bioquímica do Desenvolvimento do Sistema Nervoso, Instituto de Ciências Biológicas, Universidade Federal do Pará, Rua Augusto Corrêa No. 1, CEP: 66075-110 Belém, PA, Brazil.
| | - Felipe Pantoja Mesquita
- Lab. de Bioquímica do Desenvolvimento do Sistema Nervoso, Instituto de Ciências Biológicas, Universidade Federal do Pará, Rua Augusto Corrêa No. 1, CEP: 66075-110 Belém, PA, Brazil
| | - Paulo Robson Monteiro de Sousa
- Lab. de Planejamento e Desenvolvimento de Fármacos, Instituto de Ciências Exatas e Naturais, Universidade Federal do Pará, Rua Augusto Corrêa No. 1, CEP: 66075-110 Belém, PA, Brazil
| | - Jerônimo Lameira Silva
- Lab. de Planejamento e Desenvolvimento de Fármacos, Instituto de Ciências Exatas e Naturais, Universidade Federal do Pará, Rua Augusto Corrêa No. 1, CEP: 66075-110 Belém, PA, Brazil
| | - Claudio Nahum Alves
- Lab. de Planejamento e Desenvolvimento de Fármacos, Instituto de Ciências Exatas e Naturais, Universidade Federal do Pará, Rua Augusto Corrêa No. 1, CEP: 66075-110 Belém, PA, Brazil
| |
Collapse
|
13
|
Adamah-Biassi EB, Hudson RL, Dubocovich ML. Genetic deletion of MT1 melatonin receptors alters spontaneous behavioral rhythms in male and female C57BL/6 mice. Horm Behav 2014; 66:619-27. [PMID: 25200199 PMCID: PMC4698802 DOI: 10.1016/j.yhbeh.2014.08.012] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2014] [Revised: 08/25/2014] [Accepted: 08/29/2014] [Indexed: 10/24/2022]
Abstract
Behaviors vary over the 24h light/dark cycle and these temporal patterns reflect in part modulation by circadian neural circuits and hormones, such as melatonin. The goal of this study was to investigate the involvement of MT1 melatonin receptors in behavioral regulation by comparing male and female C57 wild type (WT) mice with C57 mice with genetic deletion of the MT1 receptor (MT1KO). A comprehensive array of fifteen distinct spontaneous behaviors was recorded continuously in the homecage over multiple days using the HomeCageScan system. Behaviors assessed were activity-like (i.e. come down, hang, jump, walk), exploration-like (i.e. dig, groom, rear up, sniff, stretch), resting-like (i.e. awake, remain low, rest, twitch) and ingestion-like (i.e. drink, eat). Phenotypic array and temporal distribution analysis revealed distinct behavioral rhythms that differed between WT and MT1KO mice. The rhythms were consistent from day to day in males and varied with the estrous cycle in females. We also studied the role of MT1 receptors on depressive and anxiety-like behaviors. Genetic deletion of MT1 receptors increased immobility time in the forced swim test and decreased the number of marbles buried in the marble burying test in both male and female C57 mice. We conclude that MT1 melatonin receptors are involved in neural pathways modulating diurnal rhythms of spontaneous behavior in the homecage as well as pathways regulating depressive and anxiolytic-like behaviors.
Collapse
Affiliation(s)
- E B Adamah-Biassi
- Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14214, USA
| | - R L Hudson
- Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14214, USA
| | - M L Dubocovich
- Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
| |
Collapse
|
14
|
Logez C, Berger S, Legros C, Banères JL, Cohen W, Delagrange P, Nosjean O, Boutin JA, Ferry G, Simonin F, Wagner R. Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes. PLoS One 2014; 9:e100616. [PMID: 24959712 PMCID: PMC4069108 DOI: 10.1371/journal.pone.0100616] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Accepted: 05/27/2014] [Indexed: 01/08/2023] Open
Abstract
The human melatonin MT1 receptor—belonging to the large family of G protein-coupled receptors (GPCRs)—plays a key role in circadian rhythm regulation and is notably involved in sleep disorders and depression. Structural and functional information at the molecular level are highly desired for fine characterization of this receptor; however, adequate techniques for isolating soluble MT1 material suitable for biochemical and biophysical studies remain lacking. Here we describe the evaluation of a panel of constructs and host systems for the production of recombinant human MT1 receptors, and the screening of different conditions for their solubilization and purification. Our findings resulted in the establishment of an original strategy using a mixture of Fos14 and CHAPS detergents to extract and purify a recombinant human MT1 from Pichia pastoris membranes. This procedure enabled the recovery of relatively pure, monomeric and ligand-binding active MT1 receptor in the near-milligram range. A comparative study based on extensive ligand-binding characterization highlighted a very close correlation between the pharmacological profiles of MT1 purified from yeast and the same receptor present in mammalian cell membranes. The high quality of the purified MT1 was further confirmed by its ability to activate its cognate Gαi protein partner when reconstituted in lipid discs, thus opening novel paths to investigate this receptor by biochemical and biophysical approaches.
Collapse
Affiliation(s)
- Christel Logez
- CNRS UMR7242/Laboratoire d'excellence MEDALIS, Institut de Recherche de l'ESBS, Biotechnologie et Signalisation Cellulaire, Université de Strasbourg, Illkirch, France
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Sylvie Berger
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Céline Legros
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Jean-Louis Banères
- CNRS UMR 5247, Institut des Biomolécules Max Mousseron (IBMM), Université de Montpellier 1 and Montpellier 2, Faculté de Pharmacie, Montpellier, France
| | - William Cohen
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Philippe Delagrange
- Unité de Recherches et Découvertes en Neurosciences, Institut de Recherche Servier, Croissy-sur-Seine, France
| | - Olivier Nosjean
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Jean A. Boutin
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
- * E-mail:
| | - Gilles Ferry
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Frédéric Simonin
- CNRS UMR7242/Laboratoire d'excellence MEDALIS, Institut de Recherche de l'ESBS, Biotechnologie et Signalisation Cellulaire, Université de Strasbourg, Illkirch, France
| | - Renaud Wagner
- CNRS UMR7242/Laboratoire d'excellence MEDALIS, Institut de Recherche de l'ESBS, Biotechnologie et Signalisation Cellulaire, Université de Strasbourg, Illkirch, France
| |
Collapse
|
15
|
Legros C, Devavry S, Caignard S, Tessier C, Delagrange P, Ouvry C, Boutin JA, Nosjean O. Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state. Br J Pharmacol 2014; 171:186-201. [PMID: 24117008 PMCID: PMC3874706 DOI: 10.1111/bph.12457] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Revised: 09/13/2013] [Accepted: 09/18/2013] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE Melatonin receptors have been extensively characterized regarding their affinity and pharmacology, mostly using 2-[(125)I]-melatonin as a radioligand. Although [(3)H]-melatonin has the advantage of corresponding to the endogenous ligand of the receptor, its binding has not been well described. EXPERIMENTAL APPROACH We characterized [(3)H]-melatonin binding to the hMT₁ and hMT₂ receptors expressed in a range of cell lines and obtained new insights into the molecular pharmacology of melatonin receptors. KEY RESULTS The binding of [(3)H]-melatonin to the hMT₁ and hMT₂ receptors displayed two sites on the saturation curves. These two binding sites were observed on cell membranes expressing recombinant receptors from various species as well as on whole cells. Furthermore, our GTPγS/NaCl results suggest that these sites on the saturation curves correspond to the G-protein coupled and uncoupled states of the receptors, whose pharmacology was extensively characterized. CONCLUSIONS AND IMPLICATIONS hMT₁ and hMT₂ receptors spontaneously exist in two states when expressed in cell lines; these states can be probed by [(3)H]-melatonin binding. Overall, our results suggest that physiological regulation of the melatonin receptors may result from complex and subtle mechanisms, a small difference in affinity between the active and inactive states of the receptor, and spontaneous coupling to G-proteins.
Collapse
Affiliation(s)
- Céline Legros
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Séverine Devavry
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
- INRA, UMR85 Physiologie de la Reproduction et des ComportementsNouzilly, France
- CNRS, UMR6175Nouzilly, France
| | - Sarah Caignard
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Clémence Tessier
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Philippe Delagrange
- Unité de Recherches en Neurosciences, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Christine Ouvry
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Jean A Boutin
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Olivier Nosjean
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| |
Collapse
|
16
|
Devavry S, Legros C, Brasseur C, Cohen W, Guenin SP, Delagrange P, Malpaux B, Ouvry C, Cogé F, Nosjean O, Boutin JA. Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂. Eur J Pharmacol 2011; 677:15-21. [PMID: 22202844 DOI: 10.1016/j.ejphar.2011.12.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2011] [Revised: 11/29/2011] [Accepted: 12/07/2011] [Indexed: 12/15/2022]
Abstract
The main melatonin receptors are two G-protein coupled receptors named MT(1) and MT(2). Having described the molecular pharmacology of the human versions of these receptors, we turned to two of the three species most useful in studying melatonin physiology: rat and sheep (a diurnal species used to understand the relationship between circadian rhythm and depression). We also employed previously used compounds to describe the mouse melatonin receptors; despite the early cloning of mouse receptors, few molecular pharmacology studies on these receptors exist. To our surprise, we detected no major differences between the data obtained from mice and those from other species.
Collapse
Affiliation(s)
- Séverine Devavry
- INRA, UMR85 Physiologie de Reproduction et des Comportements, F-37380 Nouzilly, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|